60 results about "Nanomedicine" patented technology

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

The present application relates to the field of pharmaceutical preparation and nanomedicine, and particularly relates to a kind of nano-drug composition, its combined drug delivery system and application.The nano-drug composition comprises alpha 1-AR blocker and amphiphilic nano-carrier;The alpha 1-AR blocker is loaded in the hydrophobic core formed by amphiphilic nano-carrier;The alpha 1-AR blocker is selected from one or more of prazosin, terazosin, doxazosin;The average particle size of the nano-drug composition is 220-260 nm, the polydispersity index is less than 0.3, and the encapsulation efficiency is greater than 50%.The nano-drug composition of the present application has dual functions of anti-tumor proliferation and immune microenvironment remodeling, improves the dispersion stability of the drug in physiological medium, effectively reduces the in vivo clearance rate, prolongs the circulation time, and realizes the efficient in vivo delivery of the drug.The preparation process of the nano-preparation is stable and can be produced on a large scale.

The application relates to an aptamer-membrane fusion liposome nanomedicine as well as a preparation method and application thereof, and belongs to the technical field of nanomedicine preparation. The aptamer-membrane fusion liposome nanomedicine disclosed by the application is formed based on the affinity between the cholesterol (Chol) at the 3' end of an aptamer and a liposome, has small bond energy, good spatial orientation, high selectivity and reversibility. In the aptamer-membrane fusion liposome nanomedicine, the liposome can be fused with a membrane, co-loaded auranofin (AUR) has the functions of promoting cell iron death and sensitizing radiotherapy, the immunoadjuvant aptCpG can target dendritic cells (DCs), stimulate the functions of DCs maturation and antigen presentation, and further activate subsequent immune responses. The bionic liposome nanomedicine provides a new way for improving the effectiveness of clinical malignant tumor treatment.

This invention is related to the fields of medical biotechnology, nanobiotechnology, and nanomedicine. It involves a nanomedicine product that can release HOC1 (hypochlorous acid) at the tumor site in a controlled manner to treat lung cancer. HOC1 is a potent antimicrobial and antitumor agent that can target tumor tissues while minimizing damage to healthy tissues. The produced nanoparticles have a two-layer structure: the inner layer contains alginate, PFP (perfluoropentane), and Ca(OCl)2 to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

This invention belongs to the field of biomedical nanomaterials and radiation damage drugs, specifically relating to a magnesium-ethylene glycol tetraacetic acid (EGTA) nanomedicine, its preparation method, and its applications. This study proposes using magnesium-EGTA nanomedicine to treat radiation dermatitis. EGTA's chelating ability for calcium ions is significantly higher than that of magnesium ions and other metal ions. Its unique ion selectivity provides an important theoretical basis and application potential for targeting and inhibiting mitochondrial calcium overload in the pathological process of radiation dermatitis. Magnesium ions are cofactors of many enzymes and have anti-inflammatory, collagen synthesis-promoting, and angiogenesis-enhancing effects. This study constructs a Mg-EGTA-based nanomedicine system, utilizing EGTA's stronger chelating ability for calcium ions, thereby achieving targeted regulation of mitochondrial calcium homeostasis through a calcium-magnesium ion intelligent replacement mechanism in response to calcium overload, providing new ideas and methods for the prevention and treatment of radiation dermatitis.

The application of poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers in constructing micro / nanocarriers for antitumor drugs belongs to the field of biomedical polymer materials and nanomedicine. The antitumor drugs are small-molecule chemotherapeutic agents, small-molecule photosensitizers, small-molecule immunotherapeutic agents, and small-molecule radiosensitizers. The particle size of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 10–5000 nm. The effective concentration of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 1–500 mg / kg. The antitumor mechanism of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers includes increasing the activity of effector T cells in the tumor microenvironment and increasing the concentration of cytokines such as IFN-γ at the tumor site. In the field of tumor therapy, PLA and PLGA materials composed of D-lactic acid have shown good effects in inhibiting tumor growth, prolonging the survival period of tumor-bearing mice, and activating antitumor immune responses.

This invention discloses a reactive oxygen species (ROS)-responsive nanocomposite for targeting and repairing damaged endothelium, its preparation, and its application, belonging to the field of nanomedicine technology. The nanocomposite comprises a physalicylate-copper nanoparticle core and a P-selectin-targeting polypeptide linked to the core surface via thiol-copper affinity. The physalicylate-copper nanoparticle core is prepared by coordination of physalicylate and copper ions to form a primary complex, followed by ascorbic acid reduction. This composite nanosystem can specifically recognize and accumulate in the blood vessels and peritubular regions of the kidney injury area, releasing Cu in response to high concentrations of ROS in an inflammatory environment. 2+ Together with HBT, it simultaneously achieves antioxidant and anti-inflammatory functions, promotes angiogenesis and repair, and inhibits the release of inflammatory factors and macrophage infiltration and activation, effectively blocking the fibrosis process. This system has a well-defined structure and strong targeting, and can effectively rebuild microvessels, reduce inflammation, and block the process of renal fibrosis, providing a highly efficient and precise new nanomedicine strategy for the anti-fibrotic treatment of kidney diseases.

This invention discloses a glycyrrhizic acid nanomedicine, its preparation method, and its applications, belonging to the field of biomedical nanomaterials technology. The glycyrrhizic acid nanomedicine is prepared by reacting ammonium glycyrrhizate and sodium oleate at a temperature of 15-40 °C. o Glycyrrhizate nanomedicine was prepared via a microemulsion method at temperature C. After entering tumor cells, the glycyrrhizate nanomedicine was rapidly degraded within the acidic lysosomes of the tumor cells, releasing a large amount of sodium. + The presence of glycyrrhizic acid ions and glycyrrhizic acid ions causes a surge in intracellular ion concentration and osmotic pressure, as well as the accumulation of glycyrrhizic acid within tumor cells. This induces pyroptosis in tumor cells and regulates the expression of proliferation-related proteins. Pyroptosis releases a large number of damage-associated molecular patterns (DAMPs) to trigger immune activation, while the regulation of proliferation-related protein expression inhibits tumor cell proliferation. Under the combined effect of these two factors, glycyrrhizic acid nanomedicines can not only activate the systemic anti-tumor immune response but also reduce tumor cell spread, thereby effectively inhibiting tumor growth and metastasis and enhancing the efficacy of tumor immunotherapy.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

This application provides a biantibody-modified vesicular STING agonist, its preparation method, and its application, relating to the field of polymer nanomedicine technology. The biantibody-modified vesicular STING agonist in this application includes vesicles, a STING agonist, and biantibodies. The vesicles are formed by cross-linking and assembling functionalized amphiphilic block polymers, and their lumens are negatively charged. The STING agonist is loaded into the vesicle lumen by electrostatic interactions. The biantibodies include anti-HER2 monoclonal antibodies and anti-PD1 monoclonal antibodies grafted onto the surface of the vesicles. The biantibody-modified vesicular STING agonist exhibits good biocompatibility and can enhance the killing effect of T cells on tumor cells, thereby killing tumor cells.

This application discloses a tumor-targeting nanoparticle, its preparation method, and its application, belonging to the field of tumor drug technology. The tumor-targeting nanoparticle includes a drug and a delivery carrier loading the drug, wherein the drug is atorvaquinone. The delivery carrier is prepared by coupling an intermediate product with Sulfo-SMCC-BSA. The intermediate product is obtained by reducing a thiol-modified nucleic acid aptamer, wherein the nucleic acid aptamer is EGFR aptamer. This application utilizes a EGFR-targeting nucleic acid aptamer coupled with bovine serum albumin (BSA) to encapsulate atorvaquinone, successfully constructing a novel atorvaquinone nanomedicine. This improves the targeting ability of atorvaquinone and increases its water solubility, providing a new approach for the treatment of esophageal cancer with atorvaquinone nanomedicines.

The application discloses a kind of block copolymer and its preparation method and application, the application designs and synthesizes a kind of block copolymer mPEG-PLG-COOH-CD, utilize the host molecule β-CD with guest molecule IDO-1 inhibitor (such as Epa) and Pt class chemotherapy drug (such as cisplatin) with large cavity structure, by hydrophilic and hydrophobic interaction, host-guest recognition, coordination effect common assembly into supramolecular nanomedicine.Supramolecular nanomedicine simultaneously carries Pt class chemotherapy drug and IDO-1 inhibitor.Under the action of weak acid in tumor cell, nanomedicine swells, expose drug, and high concentration of Cl- will destroy the non-covalent bond force inside nanomedicine, quickly release chemotherapy drug and IDO-1 inhibitor, while activating chemotherapy and immunotherapy, realize the efficient combination of two kinds of therapy.In situ activation of chemotherapy not only directly kills cancer cells, but also activates the anti-tumor immunity of body.

This invention discloses a nanomedicine and its application in the four-modal synergistic treatment of ER+ breast cancer, encompassing gas therapy, photothermal therapy, photodynamic therapy, and combined therapy, relating to the fields of biotechnology and new medicine. This nanomedicine uses an amphiphilic polymer as a carrier and organic compounds and photosensitizers as drug loading agents. Through the synergistic effects of four modes—photothermal, photodynamic, gas therapy, and combined therapy—it effectively inhibits the growth and metastasis of breast cancer cells. The amphiphilic polymer, based on PHHM-ADT, is modified with hydrogen sulfide gas as a donor, and its amphiphilicity allows for spontaneous assembly into nanoscale hollow, regular spheres. Utilizing the high permeability and retention effect (EPR effect) at the tumor site, it achieves efficient drug accumulation in tumor tissue. The prodrug PSF couples fulvestrant and pabuxiparin via disulfide bonds, and the photosensitizer IR808 integrates photothermal and photodynamic therapy. The synergistic effect of multiple mechanisms of action enhances the therapeutic effect.

The invention relates to the technical field of bioinformatics, in particular to a nano-drug curative effect biomarker mining system based on multi-omics data. The method comprises the following steps: firstly, acquiring multiple omics data of a subject, calculating an initial flux capacity corresponding to each enzymatic reaction, and constructing a directed graph model; further driving the directed graph model to synchronously execute supply-demand bidirectional rate updating at each temperature of the simulated temperature stepping sequence, locking the failure temperature and extracting a speed-limiting enzymatic reaction set limiting the global flux at the failure temperature; finally, mapping the rate-limiting enzymatic reaction set into a sensitive patient screening index combination; according to the method, multiple omics data are obtained to construct an enzymatic reaction directed graph, network supply and demand are deduced through temperature stepping, the failure temperature is locked, the rate-limiting enzymatic reaction is recognized, and the screening index combination is mapped, so that the mining accuracy of the nano-drug curative effect related biomarkers is improved; the technical problem that in the prior art, a sensitive patient screening index combination related to the nano-drug curative effect is difficult to determine is solved.

The invention provides an mRNA (messenger Ribonucleic Acid) medicine for inhibiting tumor stem cells and reducing the dryness of the tumor cells and a preparation method of the mRNA medicine. The mRNA medicine comprises any one or a combination of at least two of linear PTEN mRNA, self-replicating PTEN mRNA and annular PTEN mRNA; the linear PTEN mRNA comprises a 5 'UTR (Untranslated Region) sequence, a PTEN protein coding sequence and a 3' UTR sequence; the nucleotide sequence of the PTEN protein coding sequence comprises a sequence as shown in SEQ ID NO. 1. The mRNA nano-drug prepared by the invention not only has high transfection efficiency in tumor stem cells, but also can induce differentiation of the tumor stem cells and remarkably inhibit growth of the tumor stem cells; in drug-resistant tumor cells, the stemness of the drug-resistant tumor cells is inhibited, so that the sensitivity to chemotherapy, targeted antibodies, immunotherapy and the like is improved, and the killing effect of the drug is improved. The invention also shows an excellent anti-tumor effect in a human tumor cell line xenotransplantation model of the drug-resistant breast cancer in vivo, and provides a promising treatment strategy for the treatment of the drug-resistant breast cancer.

This invention relates to the field of biomedical technology, and in particular to a method for preparing and applying a nanomedicine for treating deep endometriosis. The method involves mixing ferrous ammonium sulfate, trisodium citrate, and polyethyleneimine, then adding thioacetamide and triethanolamine via a solvothermal reaction to obtain two-dimensional iron sulfide nanosheets. Dopamine hydrochloride is then added and stirred at room temperature in anhydrous ethanol to obtain polydopamine-coated iron sulfide (FP). FP is then mixed with larotrectinib and anhydrous ethanol to obtain the nanomedicine FPL for treating deep endometriosis. The synthesis method of this invention is simple and highly operable; the product is stable and reproducible; FPL exhibits good biocompatibility and biodegradability. After entering the microenvironment of deep endometriosis lesions, it can responsively release larotrectinib, effectively inhibiting the Trk signaling pathway and significantly reducing the degree of nerve infiltration; simultaneously, the anti-inflammatory effect of the FP carrier alleviates the local inflammatory response, jointly inhibiting lesion progression.

The present application relates to a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops and its preparation method and application, belong to the new auxiliary material and new dosage form technical field of drug preparation combined treatment, a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops, including temperature-sensitive gel solution and the fluorinated nanomedicine uniformly dispersed in the temperature-sensitive gel solution;The fluorinated nanomedicine is the nanometer assembly formed by intermolecular interaction co-assembly of dexamethasone and fluorinated side chain prodrug;The structural formula of the fluorinated side chain prodrug is as shown below.The temperature-sensitive hydrogel eye drops of the present application further regulate iron death by synergistic anti-inflammatory and antioxidant effects, provide new strategy for treating dry eye.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

This invention relates to the technical field of nanomedicine synthesis and discloses a method for synthesizing nanomedicines for the treatment of rheumatoid arthritis, comprising the following steps: S10: obtaining or preparing high-purity, small-particle-size CaO2 nanoparticles; S20: encapsulating the CaO2 nanoparticles in a ZIF67 system to obtain CaO2@ZIF67; S30: dissolving methotrexate in methanol to obtain an MTX additive solution; dissolving CaO2@ZIF67 in methanol, then adding the MTX additive solution dropwise, and stirring thoroughly; finally, purifying, washing, and drying the obtained product to obtain CaO2@MTX@ZIF67. Targeting the two main pathological features of rheumatoid arthritis, namely inflammation and hypoxic microenvironment, this invention uses ZIF67-loaded calcium peroxide combined with methotrexate to treat the inflammatory sites of rheumatoid arthritis. The constructed product can inhibit the expression of tumor necrosis factor-α / interleukin-6, overcome the hypoxic nature of rheumatoid arthritis, and achieve the technical characteristics of alleviating inflammatory symptoms and altering disease progression, low cost, few side effects, and long-term treatment.

This invention relates to the application of a melanin-catalase nanocomposite (MAC) targeting intestinal mucosal neutrophils in the preparation of drugs for treating inflammatory bowel disease, belonging to the field of novel applications of nanomedicine. It addresses the challenges of catalase oral delivery being easily degraded and inactivated by gastrointestinal proteases and difficult to precisely target neutrophils. This invention is the first to discover a MAC prepared by in-situ polymerization of dopamine on the surface of catalase, which can be used for the treatment of inflammatory bowel disease. This nanocomposite, through oral delivery, precisely targets intestinal mucosal infiltrating neutrophils and maintains structural stability in the gastrointestinal fluid environment, effectively protecting catalase activity. It actively targets intestinal mucosal infiltrating neutrophils through the high affinity of melanin for dopamine D2 receptors, synergistically exerting a triple effect of hydrogen peroxide decomposition, hypochlorous acid scavenging, and iron ion chelation, effectively inhibiting the formation of extracellular traps in neutrophils.

This invention discloses a tubing connection structure for nanomedicine preparation, comprising: at least two inlet tubes; a microfluidic chip having an aqueous solution inlet, a lipid solution inlet, a mixing channel, and a solution outlet; a fluid control unit, each fluid control unit having a fluid channel connected to a corresponding inlet tube and to either the aqueous solution inlet or the lipid solution inlet of the microfluidic chip; a fluid drive unit, each fluid drive unit including two syringes moving in opposite directions, the injection ends of the two syringes respectively connected to the fluid channel of the fluid control unit; the microfluidic chip connected to a sample recovery tube; the sample recovery tube being sequentially connected from the liquid output direction to a dilution phase input tube and a waste product recovery tube; and clamps provided on both the waste product recovery tube and the sample recovery tube. Through the above-mentioned design, this invention effectively ensures the continuity of solution delivery, thereby improving the preparation effect of nanomedicines.

The present application relates to a kind of drug combination products for enhancing the therapeutic effect of nanomedicine, belong to nanomedicine technical field.The drug combination product includes following (1), (2) and (3): (1) stimulus-responsive nanomedicine;(2) mononuclear phagocyte system blocker;(3) exogenous reducing substance.The drug combination product provided by the present application carries out the regulation in time sequence to the in vivo delivery and release process of nanomedicine by "first block then loose" delivery strategy, realizes the effective accumulation and intelligent release of nanomedicine in target tissue, to improve the therapeutic effect.

The invention provides an application research of nano layered double hydroxides (LDH) for immunoregulation of interleukin-6 (IL-6) to promote liver regeneration, and based on the biomedical potential of the layered double hydroxide nano material, the action mechanism of the layered double hydroxides nano material in liver regeneration is systematically clarified. According to the application, a potential molecular mechanism of promoting liver regeneration by LDH is disclosed for the first time from the perspectives of immunoregulation and signal transduction, and a new theoretical basis and an experimental basis are provided for application of a nano material in tissue regeneration and liver function reconstruction. In the future, physicochemical properties and targeting of LDH can be further optimized, interaction with immune cells, signal transduction network remodeling and long-term safety of LDH can be deeply discussed in combination with a multi-omics technology and an in-vivo imaging means, and a direction is provided for developing novel immunoregulation type nano-drugs.

This invention discloses a miR-141 / near-infrared light dual-response synergistic drug delivery system, relating to the fields of biomedicine and nanomedicine. The system uses DNA-modified gold nanocages as carriers, loading doxorubicin (a chemotherapy drug) and methylene blue (a photosensitizer). H-type DNA nanolocks formed by thiol-modified A and B chains achieve specific recognition of miR-141 and dual response to near-infrared light. miR-141 binding triggers initial unwinding of the nanolocks, followed by complete unwinding and drug release via 808nm near-infrared light irradiation (photothermal effect). A 650nm laser excites methylene blue to generate reactive oxygen species, simultaneously completing quantitative detection of miR-141 (fluorescence / SERS signal complementarity) and synergistic treatment in three modes: chemotherapy + photothermal + photodynamic therapy. In vitro experiments show a miR-141 detection sensitivity of 5.0 × 10⁻⁶. ‑12 M, with a dual-response drug release rate exceeding 60%; in vivo experiments have demonstrated a tumor inhibition rate exceeding 70% and good biocompatibility. This system solves the problems of single-response and separation of diagnosis and treatment in existing delivery systems, and is suitable for precision treatment of miR-141 positive solid tumors such as MCF-7.

This invention discloses a nanomedicine for targeted combination therapy of osteosarcoma, having a core-shell structure, comprising: a nanomedicine core and a biomimetic outer shell. The nanomedicine core is loaded with the active ingredient capsaicin and a near-infrared fluorescent dye; the biomimetic outer shell is an osteosarcoma-derived tumor cell membrane coating the surface of the nanomedicine core. This invention also provides a method for preparing the nanomedicine for targeted combination therapy of osteosarcoma and its applications. The nanomedicine for targeted combination therapy of osteosarcoma provided by this invention possesses excellent "homing" and immune escape capabilities, significantly overcoming the bottleneck of targeted delivery of osteosarcoma, exhibiting significantly better tumor-suppressing effects than single therapy, significantly improving the physicochemical properties and stability of the hydrophobic active ingredient, and possessing good biocompatibility and safety, reducing systemic toxicity.

This invention discloses the application of a gold-copper alloy nanoparticle in vivo behavior regulation system in nanomedicine carriers. The system comprises gold, copper, and ligands; wherein the ligands are selected from compact small-molecule thiol ligands or thiolized polyethylene glycol ligands, with the thiolized polyethylene glycol ligands having a molecular weight of 800–2000 Da. The system is prepared via a one-step reduction method, a mild and simple process. Studies show that, compared to single gold nanoparticles, this alloy system significantly prolongs the blood circulation half-life and improves the enrichment efficiency in tumor tissues while maintaining excellent biocompatibility primarily through renal clearance. This invention solves the problem of limited efficacy of ultrasmall nanomedicines due to rapid metabolism, providing a scientific basis for the rational design of drug carriers for tumor diagnosis and treatment.